Clinical Microbiology and Antimicrobial Chemotherapy. 2007; 9(1):73-80
Invasive fungal infections are still a growing problem of modern medicine. The prevalence of invasive fungal infections significantly increased during the last few decades concurrently with the increasing number of immunocompromised patients. The number of available and approved systemic antimycotics is not that big, and a progress in the development of new preparations does not completely conform to the rates of invasive mycoses. In this article an attempt to briefly underline the key aspects regarding current and anticipated systemic antimycotics, in order to help the clinicians to make a correct drug choice in different clinical situations, was made.